Design and development of dual functional colon targeted eudragit/chitosan nanoparticles: a QbD approach
By: Patel, Priyadarshini
.
Contributor(s): Patel, Tejas.
Publisher: Bangalore Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(4), Oct-Dec.Description: 1063-1075p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Aim: The goal of this study was to develop colon-targeted nanoparticulate systems of
the anti-inflammatory agent Quercetin (QU) and evaluate the formulation for various
parameters that would allow the active ingredient to be released at a predetermined
time and location with better pharmaceutical and therapeutic properties. Materials and
Methods: Quercetin-loaded chitosan nanoparticles were formulated for this purpose using
the ionic gelation method by employing Central Composite Design. To coat Eudragit S 100
(ES 100) on an optimised formulation of quercetin loaded chitosan nanoparticles (QLCN),
the oil in oil solvent evaporation process was used. Particle size (PS), polydispersity index
(PDI), scanning electron microscopy (SEM), and drug release (% DR) were evaluated
to characterize the nanoparticles. Results: Quercetin loaded chitosan nanoparticles has
an average PS 114.2 ± 1.42 nm and polydispersity index 0.396 ± 0.02, whereas
Eudragit coated nanoparticles shows PS 330.2± 0.40 nm and polydispersity index
0.412 ± 0.02. Surface morphology of prepared nanoparticles were confirmed using
SEM. According to an
in vitro drug release analysis of nanostructured formulations, the
ES 100 coating on QLCN inhibits the release of quercetin in the upper gastrointestinal
system, demonstrating good colon drug targeting. Conclusion: According to an
in vitro
release study of nanoparticle formulations, the ES 100 coating on QLCN limits the
release of quercetin in the upper gastrointestinal system, demonstrating effective colon
drug targeting.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2023-0103 |
Aim: The goal of this study was to develop colon-targeted nanoparticulate systems of
the anti-inflammatory agent Quercetin (QU) and evaluate the formulation for various
parameters that would allow the active ingredient to be released at a predetermined
time and location with better pharmaceutical and therapeutic properties. Materials and
Methods: Quercetin-loaded chitosan nanoparticles were formulated for this purpose using
the ionic gelation method by employing Central Composite Design. To coat Eudragit S 100
(ES 100) on an optimised formulation of quercetin loaded chitosan nanoparticles (QLCN),
the oil in oil solvent evaporation process was used. Particle size (PS), polydispersity index
(PDI), scanning electron microscopy (SEM), and drug release (% DR) were evaluated
to characterize the nanoparticles. Results: Quercetin loaded chitosan nanoparticles has
an average PS 114.2 ± 1.42 nm and polydispersity index 0.396 ± 0.02, whereas
Eudragit coated nanoparticles shows PS 330.2± 0.40 nm and polydispersity index
0.412 ± 0.02. Surface morphology of prepared nanoparticles were confirmed using
SEM. According to an
in vitro drug release analysis of nanostructured formulations, the
ES 100 coating on QLCN inhibits the release of quercetin in the upper gastrointestinal
system, demonstrating good colon drug targeting. Conclusion: According to an
in vitro
release study of nanoparticle formulations, the ES 100 coating on QLCN limits the
release of quercetin in the upper gastrointestinal system, demonstrating effective colon
drug targeting.
Click on an image to view it in the image viewer
There are no comments for this item.